← All trials
NCT05271240
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 27, 2022
- Primary completion
- Apr 1, 2027
- Completion date
- Apr 1, 2028
- First posted
- Mar 8, 2022
- Last posted
- May 11, 2022
- Enrollment
- 432
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Northwell HealthLead sponsor
- Northwell HealthReponsible party - principal investigator
- Lenox Hill HospitalOfficial
- Northwell HealthSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.